// App-Quantinova.ai

TPS8589 : Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for patients with extensive-stage small cell lung cancer.

Researchers

Presenter

  • Chul Kim

Principal Investigators

  • Deepa Suresh Subramaniam

  • Stephen V. Liu

  • Giuseppe Giaccone

Medical Centers

  • Georgetown University, Washington, DC

  • Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC

  • Georgetown University Medical Center, Washington, DC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Lu-DOTATATE

  • Nivolumab

  • Netspot

Outcome

  • N/A

Study Design

  • Cross Over

  • Multicenteric

Phase

  • NA

Study Id's

  • NCT03325816

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved